Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Idea Of The Day -- Ignore unavailable to you. Want to Upgrade?

To: ViperChick Secret Agent 006.9 who wrote (18049)	4/19/1998 8:14:00 PM
From: Nancy	Read Replies (1) \| Respond to of 50167

lisa, fundamentally, mrk is not very strong in terms of new drugs in the pipeline, while they do have new drugs coming out, none of them has potential of a killer drug a la wla's lipitor or pfe's viagra. wla's lipitor continuously takes market shares from mrk's older cholestrol control drug. (forgot the name) giving current mkt environment though, mrk probably wont fall too far for these reasons : relative cheap valuation in the group stock has virtually only gained 20 % since jan 97, not much air in it. a dow stocks (could soon become a dow dog that when those dow dog ports come into quarterly rotation, they might pick up mrk) it probably would just drift.